Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR).

Full DD Report for ALDR

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALDR)

Research Report Identifies Armstrong World Industries, Empire State Realty Trust, Alder BioPharmaceuticals, Cadence, World Wrestling Entertainment, and Cato with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Armstrong World Industries, Inc. (NYSE:AWI), Empire State Realty Trust, In...
Source: GlobeNewswire
Date: May, 17 2018 07:40
Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come...
Source: SeekingAlpha
Date: May, 16 2018 07:38
Alder Biopharmaceuticals Inc. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Alder Biopharmaceuticals Inc. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 10 2018 15:07
Alder Biopharmaceuticals' (ALDR) CEO Paul Cleveland on Q1 2018 Results - Earnings Call Transcript
Alder Biopharmaceuticals (ALDR) Q1 2018 Earnings Conference Call May 08, 2018, 05:00 PM ET Executives Ashwin Agarwal - VP, Corporate Strategy Larry Benedict - Principal Accounting Officer and EVP Paul Cleveland - Interim President, CEO & Director Roger Cady - VP of Neurolog...
Source: SeekingAlpha
Date: May, 08 2018 23:32
Alder BioPharmaceuticals® Reports First Quarter 2018 Financial and Operating Results
- 12-Month Data Presented at American Academy of Neurology (AAN) Annual Meeting Demonstrated Eptinezumab Further Reduced Migraine Risk Following Third and Fourth Quarterly Infusions - - Biologics License Application (BLA) Submission Expected in Q1 2019 - - Key Clinical Data Miles...
Source: GlobeNewswire
Date: May, 08 2018 16:07
Alder BioPharmaceuticals® to Present at the 2018 Bank of America Merrill Lynch Health Care Conference
BOTHELL, Wash., May 07, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. Clevela...
Source: GlobeNewswire
Date: May, 07 2018 08:30
Alder BioPharmaceuticals® to Host Conference Call to Discuss First Quarter 2018 Financial and Operating Results
BOTHELL, Wash., April 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first quarter 2018 financial and operating r...
Source: GlobeNewswire
Date: April, 30 2018 08:30
Allergan Hits Another Home Run For 2nd Migraine Study
Recently, Allergan ( AGN ) announced positive results from its second phase 3 study treating patients with acute migraine. The company used its drug ubrogepant to treat these patients. This is highly positive, because now it has all it needs to file an NDA to the FDA by 2019. That's why I be...
Source: SeekingAlpha
Date: April, 30 2018 04:22
Alder BioPharmaceuticals® Appoints Jeremy Green to its Board of Directors
BOTHELL, Wash., April 26, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the “Company”), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that its Boar...
Source: GlobeNewswire
Date: April, 26 2018 08:30
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
BOTHELL, Wash., April 25, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new data from its PROMISE 1 Phase 3 clinical trial evaluating eptine...
Source: GlobeNewswire
Date: April, 25 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1815.0014.5515.148914.401877,368
2018-05-1715.0014.5515.148914.401877,368
2017-06-2018.8519.1020.0018.701,543,354
2017-06-1917.5018.8018.9517.50984,923
2017-06-1617.3517.5018.0017.20940,767

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-24248,615333,32774.5859Short
2018-05-2358,37493,44762.4675Short
2018-05-22198,285266,84174.3083Short
2018-05-21633,347877,33672.1898Short
2018-05-18268,269485,51555.2545Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALDR.


About Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR)

Logo for Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ALDR)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: May, 04 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 26 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: April, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: March, 23 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 20 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 26 2018

       

       


      Daily Technical Chart for (NASDAQ: ALDR)

      Daily Technical Chart for (NASDAQ: ALDR)


      Stay tuned for daily updates and more on (NASDAQ: ALDR)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ALDR)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      Monsta Trader
      @MonstaTrader

       

       


      Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALDR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of ALDR and does not buy, sell, or trade any shares of ALDR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/